Hims & Hers In Talks With Novo Nordisk To Sell Wegovy Injections, New Obesity Pill

Hims & Hers stock rose 6% in post-market trading Monday after the telehealth company said it is in active talks with Novo Nordisk to make Wegovy injections and the drugmaker’s upcoming oral obesity pill available through its platform. Novo Nordisk expects to launch the oral drug in the U.S. next year, pending FDA approval.

In its third-quarter earnings report, Hims & Hers confirmed that discussions with Novo Nordisk are ongoing and no definitive agreement has been signed. The announcement follows the end of a prior collaboration in June, when Novo Nordisk terminated a partnership over concerns about Hims & Hers offering compounded, lower-cost versions of GLP-1 drugs such as Wegovy.

CEO Andrew Dudum said the company is optimistic about reengaging with Novo Nordisk and other drugmakers as new weight loss therapies, including next-generation GLP-1 and GIP treatments, advance through clinical trials. Analysts at Zacks Investment Research said renewed talks with Novo Nordisk clear up uncertainty and strengthen Hims’ growing weight loss business, which CFO Yemi Okupe projects will generate about $725 million in 2025.

Hims & Hers continues to expand its weight loss offerings, including compounded semaglutide and new microdosing options. Dudum said the company has reduced prices for compounded GLP-1 treatments by up to 20% to improve accessibility, emphasizing its goal of creating a “high-touch, patient-centric experience.”

The telehealth platform, which offers care across mental health, dermatology, sexual health, and primary care, reported third-quarter revenue of $599 million—up 49% year over year and above Wall Street expectations—with adjusted EBITDA of $78.4 million, up 53%. Net income was $15.8 million, or 6 cents per share. Subscriber numbers climbed 21% year over year to more than 2.5 million, with personalized solution users up 50%.

The company narrowed its full-year revenue forecast to $2.335–$2.355 billion and expects adjusted EBITDA between $307 million and $317 million. Looking ahead, Hims & Hers plans to roll out whole-body lab testing by the end of the year and introduce a longevity specialty in 2026, offering therapies and diagnostics targeting cardiometabolic health, performance, and disease prevention. Dudum said these initiatives reflect a broader mission to make advanced, personalized healthcare accessible to everyone, not just the affluent few.